Research progress on N6-methyladenosine and ferroptosis in childhood combined allergic rhinitis and asthma syndrome.
10.7499/j.issn.1008-8830.2407062
- Author:
Jing-Yi LI
1
;
Yu-Jian LI
1
;
Sheng-Lin LAI
1
;
Xuan KAN
1
Author Information
1. Department of Pediatrics, General Hospital of Tianjin Medical University, Tianjin 300052, China.
- Publication Type:English Abstract
- Keywords:
Allergic asthma;
Allergic rhinitis;
Child;
Combined allergic rhinitis and asthma syndrome;
Ferroptosis;
N6-methyladenosine
- MeSH:
Humans;
Adenosine/physiology*;
Asthma/etiology*;
Ferroptosis;
Rhinitis, Allergic/etiology*;
Child
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(2):242-247
- CountryChina
- Language:Chinese
-
Abstract:
Combined allergic rhinitis and asthma syndrome (CARAS) is one of the common chronic airway inflammatory diseases in children. With the development of epigenetics, research on CARAS has gradually extended from protein levels to molecular levels, such as transcription and post-transcriptional regulation. N6-methyladenosine (m6A) methylation and ferroptosis have emerged as promising research hotspots in recent years, playing crucial roles in tumors, growth and development, and allergic diseases. This paper aims to summarize the characteristics of m6A and ferroptosis, along with their roles in the onset and progression of CARAS in children, thereby providing new insights and strategies for the diagnosis and treatment of childhood CARAS.
